Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial

In this single-arm, multicenter phase 2 trial, 111 patients in the per-protocol population with previously untreated, resectable clinical stage 2 or 3 dMMR colon cancer received neoadjuvant ipilimumab plus nivolumab. Three-year disease-free survival and 5-year overall survival were both 100%. Among patients with available plasma, ctDNA was detected in 99 of 108 (92%) at baseline, cleared before surgery in 80 of 97 (82%) after the second cycle, and was not detected after surgery in any assessed patient.

The LancetPubMed 42906564DOI 10.1016/S0140-6736(26)01602-8